Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

288 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study.
Kersten MJ, Driessen J, Zijlstra JM, Plattel WJ, Morschhauser F, Lugtenburg PJ, Brice P, Hutchings M, Gastinne T, Liu R, Burggraaff CN, Nijland M, Tonino SH, Arens AIJ, Valkema R, van Tinteren H, Lopez-Yurda M, Diepstra A, De Jong D, Hagenbeek A. Kersten MJ, et al. Among authors: driessen j. Haematologica. 2021 Apr 1;106(4):1129-1137. doi: 10.3324/haematol.2019.243238. Haematologica. 2021. PMID: 32273476 Free PMC article. Clinical Trial.
Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia.
Kater AP, van Oers MHJ, van Norden Y, van der Straten L, Driessen J, Posthuma WFM, Schipperus M, Chamuleau MED, Nijland M, Doorduijn JK, Van Gelder M, Hoogendoorn M, De Croon F, Wittebol S, Kerst JM, Marijt EWA, Raymakers RAP, Schaafsma MR, Dobber JA, Kersting S, Levin MD; HOVON CLL study group. Kater AP, et al. Among authors: driessen j. Haematologica. 2019 Jan;104(1):147-154. doi: 10.3324/haematol.2018.193854. Epub 2018 Aug 16. Haematologica. 2019. PMID: 30115656 Free PMC article. Clinical Trial.
Extracellular vesicle miRNA predict FDG-PET status in patients with classical Hodgkin Lymphoma.
Drees EEE, Roemer MGM, Groenewegen NJ, Perez-Boza J, van Eijndhoven MAJ, Prins LI, Verkuijlen SAWM, Tran XM, Driessen J, Zwezerijnen GJC, Stathi P, Mol K, Karregat JJJP, Kalantidou A, Vallés-Martí A, Molenaar TJ, Aparicio-Puerta E, van Dijk E, Ylstra B, Groothuis-Oudshoorn CGM, Hackenberg M, de Jong D, Zijlstra JM, Pegtel DM. Drees EEE, et al. Among authors: driessen j. J Extracell Vesicles. 2021 Jul;10(9):e12121. doi: 10.1002/jev2.12121. Epub 2021 Jul 15. J Extracell Vesicles. 2021. PMID: 34295456 Free PMC article.
The Impact of Semiautomatic Segmentation Methods on Metabolic Tumor Volume, Intensity, and Dissemination Radiomics in 18F-FDG PET Scans of Patients with Classical Hodgkin Lymphoma.
Driessen J, Zwezerijnen GJC, Schöder H, Drees EEE, Kersten MJ, Moskowitz AJ, Moskowitz CH, Eertink JJ, Vet HCW, Hoekstra OS, Zijlstra JM, Boellaard R. Driessen J, et al. J Nucl Med. 2022 Sep;63(9):1424-1430. doi: 10.2967/jnumed.121.263067. Epub 2022 Jan 6. J Nucl Med. 2022. PMID: 34992152 Free PMC article.
Blood-circulating EV-miRNAs, serum TARC, and quantitative FDG-PET features in classical Hodgkin lymphoma.
Drees EEE, Driessen J, Zwezerijnen GJC, Verkuijlen SAWM, Eertink JJ, van Eijndhoven MAJ, Groenewegen NJ, Vallés-Martí A, de Jong D, Boellaard R, de Vet HCW, Pegtel DM, Zijlstra JM. Drees EEE, et al. Among authors: driessen j. EJHaem. 2022 Apr 28;3(3):908-912. doi: 10.1002/jha2.432. eCollection 2022 Aug. EJHaem. 2022. PMID: 36051072 Free PMC article.
Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP.
Driessen J, Kersten MJ, Visser L, van den Berg A, Tonino SH, Zijlstra JM, Lugtenburg PJ, Morschhauser F, Hutchings M, Amorim S, Gastinne T, Nijland M, Zwezerijnen GJC, Boellaard R, de Vet HCW, Arens AIJ, Valkema R, Liu RDK, Drees EEE, de Jong D, Plattel WJ, Diepstra A; HOVON Lunenburg Lymphoma Phase I/II Consortium (LLPC). Driessen J, et al. Leukemia. 2022 Dec;36(12):2853-2862. doi: 10.1038/s41375-022-01717-8. Epub 2022 Oct 14. Leukemia. 2022. PMID: 36241696
Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score-matched analysis.
Driessen J, de Wit F, Herrera AF, Zinzani PL, LaCasce AS, Cole PD, Moskowitz CH, García-Sanz R, Fuchs M, Müller H, Borchmann P, Santoro A, Schöder H, Zijlstra JM, Hutten BA, Moskowitz AJ, Kersten MJ. Driessen J, et al. Blood Adv. 2024 Jun 11;8(11):2740-2752. doi: 10.1182/bloodadvances.2023012145. Blood Adv. 2024. PMID: 38502227 Free PMC article.
288 results